Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283135 | 0.89 | TDP1 (0.66) | TDP1L3MBTL1ALDH1A1ALDH2PKM | |
| SCHEMBL614087 | 0.85 | TDP1 (0.48) | TDP1L3MBTL1MAOBCYP1B1BCHE | |
| SCHEMBL14044517 | 0.85 | TDP1 (0.60) | TDP1L3MBTL1MAOBCYP1B1ALDH1A1 | |
| SCHEMBL6285932 | 0.84 | TDP1 (0.69) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL2202509 | 0.84 | RAB9A (0.57) | TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL6283360 | 0.83 | TDP1 (0.71) | TDP1L3MBTL1 | |
| SCHEMBL10237575 | 0.83 | TDP1 (0.51) | TDP1L3MBTL1MAOBCYP1B1ALDH1A1 | |
| SCHEMBL30371663 | 0.82 | TDP1 (0.86) | TDP1L3MBTL1MAOBCYP1B1ACHE | |
| SCHEMBL45050 | 0.82 | TDP1 (0.86) | TDP1L3MBTL1MAOBCYP1B1ACHE | |
| SCHEMBL2754682 | 0.82 | CYP1B1 (0.61) | TDP1L3MBTL1CYP1B1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669246-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8669246-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | TDP1 4071/4885L3MBTL1 2082/4885MAOB 1796/4885 |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | TDP1 4112/4885L3MBTL1 2071/4885MAOB 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.